Clinical trial NCT00582400 (phase 2, status: terminated)
Conditions: carcinoma, hepatocellular
ICD codes: C22.0, C4A.9, C7B.1, C4A.0, C4A.31, C4A.51, C4A.8
Drugs: arsenic trioxide
SMILES: O=[As]O[As]=O
Reason stopped: 
    recruiting or enrolling participants has halted prematurely and will not resume; participants
    are no longer being examined or treated
  
Eligibility criteria:

        Inclusion Criteria:

          -  Signed Informed Consent

          -  ECOG/Zubrod/SWOG Performance Status < 2

          -  Life expectancy > 12 weeks

          -  Male or female' age >18 years Subjects of childbearing potential must be using an
             effective means of contraception.

          -  Histologic diagnosis of HCC or cholangiocarcinoma that is locally advanced but cannot
             be treated adequately by radiotherapy or surgery (more than one lesion, portal vein
             involvement, or poor hepatic reserve); or metastatic disease or an AFB > 20 w/CT scan
             consistent with HCC

          -  Renal function: Serum creatinine < 2.0 mg/dl

          -  Serum calcium < 12 mg/dl

          -  Serum electrolytes, including magnesium and potassium, within normal limits

        Exclusion Criteria:

          -  Pregnant or lactating females

          -  Myocardial infarction or ischemia within the 6 months before Cycle 0' Day 0

          -  Uncontrolled' clinically significant dysrhythmia

          -  Known left ventricular Ejection Fraction below the normal limit for UTMB

          -  History of prior malignancy within the prior five years, with the exception of
             non-melanoma carcinomas of the skin, and carcinoma in situ of the cervix

          -  More than one prior chemotherapy regimens for liver cancer (subjects who are receiving
             antineoplastic agents for non-malignant conditions, such as methotrexate for
             rheumatoid arthritis, must be off such therapy for at least four weeks prior to
             receiving the first dose of protocol therapy, and may not receive such therapy while
             participating in this protocol)

          -  Receiving any other chemotherapy or cytokine therapy

          -  Subjects receiving radiation therapy (Trisenox will be held during the administration
             of palliative or emergent radiotherapy)

          -  Subjects who have received radiofrequency ablation or hepatic arterial embolization
             within the past four weeks (patients who have received prior RFA or HAE are otherwise
             eligible)

          -  Prior radiotherapy to an indicator lesion unless there is objective evidence of tumor
             growth in that lesion

          -  Uncontrolled metastatic disease of the central nervous system

          -  Prior and on-going Grade 2-4 peripheral neuropathy, as measured by NCI Common Toxicity
             Criteria version 3.0

          -  Radiotherapy within the 2 weeks before Cycle 1' Day 1

          -  Surgery within the 2 weeks before Cycle 1' Day 1

          -  Any co morbid condition that' in the view of the attending physician' renders the
             subject at high risk from treatment complications